Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.

@article{Lankford2012EfficacyAS,
  title={Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.},
  author={A. Lankford and Roberta L. Rogowski and B. Essink and E. Ludington and H. Heith Durrence and T. Roth},
  journal={Sleep medicine},
  year={2012},
  volume={13 2},
  pages={
          133-8
        }
}
  • A. Lankford, Roberta L. Rogowski, +3 authors T. Roth
  • Published 2012
  • Medicine
  • Sleep medicine
  • INTRODUCTION The efficacy and safety of doxepin (DXP), a histamine H(1) receptor antagonist, was evaluated in elderly adults with sleep maintenance insomnia. METHODS This was a randomized, double-blind, placebo-controlled outpatient trial. Elderly adults meeting DSM-IV-TR criteria for primary insomnia were randomized to four weeks of nightly treatment with either DXP 6 mg (N=130) or placebo (PBO; N=124). Efficacy was assessed using patient self-report instruments and clinician ratings… CONTINUE READING
    Insomnia in Elderly Patients: Recommendations for Pharmacological Management
    • 19

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 16 REFERENCES
    Efficacy and safety of doxepin 6 mg in a model of transient insomnia.
    • 29
    The effects of doxepin HCl on sleep and depression.
    • 40
    Insomnia causes, consequences, and therapeutics: An overview
    • 247